Therapeutic Area: Hematology
Highest Development Status: Approved Product Type: Small molecule
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 07, 2020
Cipla has acquired the four brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in the women's health segment, Cipla said in a filing to the BSE.